COVID-19 Active Research Experience (CARE)
Registry to Study Factors That May Impact COVID-19 Occurrence and Severity
1 other identifier
observational
35,278
2 countries
2
Brief Summary
COVID-19 Active Research Experience (CARE) is an observational, direct-to-participant, web-based, longitudinal study of adults with COVID-19 or COVID-19 like illness or who were vaccinated against COVID-19 to better understand risk factors, symptoms, and treatments for COVID-19 illness and vaccine safety and effectiveness.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 2, 2020
CompletedFirst Submitted
Initial submission to the registry
April 28, 2020
CompletedFirst Posted
Study publicly available on registry
April 29, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 23, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
February 23, 2023
CompletedMarch 28, 2023
March 1, 2023
2.9 years
April 28, 2020
March 27, 2023
Conditions
Outcome Measures
Primary Outcomes (5)
COVID-19 symptom occurrence and severity
Occurrence and severity of potential COVID-19 symptoms as reported by participants in the survey
12 months
COVID-19 treatments
Prescription treatments for COVID-19 as reported by participants in the survey
12 months
COVID-19 risk factors
Assess potential role of comorbidities and concomitant medications on COVID-19 occurrence and severity
12 months
Occurrence and severity of COVID-19 infection after vaccination
Occurrence and severity of COVID-19 infection as reported by participants after SARS-CoV-2 vaccine
12 months
Occurrence of medically attended events after vaccination
Occurrence of medically attended events as reported by participants after after SARS-CoV-2 vaccine
1 month
Eligibility Criteria
Adults living in the US or UK who have COVID-19 or COVID-19 like symptoms, were vaccinated against COVID-19, or were exposed to COVID-19.
You may qualify if:
- Adult (18 years or older)
- Currently living in the US or UK
- Have regular access to a computer, smartphone or tablet and sufficient internet to support registry demands (note: this registry is designed to operate well even in regions with low bandwidth)
- Willing and able to provide informed consent
- Willing and able to follow the procedures of the study
- Participants must also meet at least one of the following conditions:
- Have COVID-19 or COVID-19 like symptoms
- Received a COVID-19 vaccine
- Potential exposure to COVID-19
You may not qualify if:
- Unable to provide informed consent
- Unable to perform the requested study tasks and unable or unwilling to assign a proxy informant to complete the tasks
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Iqvia Pty Ltdlead
Study Sites (2)
IQVIA
Cambridge, Massachusetts, 02139, United States
IQVIA
London, United Kingdom
Related Publications (5)
Dreyer NA, Knuth KB, Xie Y, Reynolds MW, Mack CD. COVID-19 Vaccination Reactions and Risk of Breakthrough Infections Among People With Diabetes: Cohort Study Derived From Community Reporters. JMIR Diabetes. 2024 Feb 27;9:e45536. doi: 10.2196/45536.
PMID: 38412008DERIVEDLargent J, Xie Y, Knuth KB, Toovey S, Reynolds MW, Brinkley E, Mack CD, Dreyer NA. Cognitive and other neuropsychiatric symptoms in COVID-19: analysis of person-generated longitudinal health data from a community-based registry. BMJ Open. 2023 Jun 19;13(6):e069118. doi: 10.1136/bmjopen-2022-069118.
PMID: 37336535DERIVEDReynolds MW, Secora A, Joules A, Albert L, Brinkley E, Kwon T, Mack C, Toovey S, Dreyer NA. Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case-control design. J Comp Eff Res. 2022 Nov;11(16):1161-1172. doi: 10.2217/cer-2022-0069. Epub 2022 Sep 23.
PMID: 36148919DERIVEDReynolds MW, Xie Y, Knuth KB, Mack CD, Brinkley E, Toovey S, Dreyer NA. COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness. Infect Drug Resist. 2022 Sep 3;15:5167-5182. doi: 10.2147/IDR.S373183. eCollection 2022.
PMID: 36090603DERIVEDDreyer N, Reynolds MW, Albert L, Brinkley E, Kwon T, Mack C, Toovey S. How frequent are acute reactions to COVID-19 vaccination and who is at risk? Vaccine. 2022 Mar 15;40(12):1904-1912. doi: 10.1016/j.vaccine.2021.12.072. Epub 2022 Feb 9.
PMID: 35177299DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nancy Dreyer, PhD, MPH
Iqvia Pty Ltd
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 28, 2020
First Posted
April 29, 2020
Study Start
April 2, 2020
Primary Completion
February 23, 2023
Study Completion
February 23, 2023
Last Updated
March 28, 2023
Record last verified: 2023-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- Data will be available during conduct of the study and two years following study completion.
- Access Criteria
- Qualified researchers that have undergone a review process may submit requests to the IQVIA Registry Data Governance Committee (DGC) requesting approval and access for specific research purposes.
It is anticipated that external researchers may want to leverage these data for public health and life sciences research. The intent is to provide limited data access to qualified researchers for research that has gone through a review process.